|
1
|
Jemal A, Thomas A, Murray T and Thun M:
Cancer statistics, 2002. CA Cancer J Clin. 52:23–47. 2002.
View Article : Google Scholar
|
|
2
|
Murdoch WJ, Van Kirk EA and Alexander BM:
DNA damages in ovarian surface epithelial cells of ovulatory hens.
Exp Biol Med (Maywood). 230:429–433. 2005.PubMed/NCBI
|
|
3
|
Deraco M, Baratti D, Laterza B, Balestra
MR, Mingrone E, Macri A, Virzi S, Puccio F, Ravenda PS and Kusamura
S: Advanced cytoreduction as surgical standard of care and
hyperthermic intraperitoneal chemotherapy as promising treatment in
epithelial ovarian cancer. Eur J Surg Oncol. 37:4–9. 2011.
View Article : Google Scholar
|
|
4
|
Johnatty SE, Beesley J, Paul J, Fereday S,
Spurdle AB, Webb PM, Byth K, Marsh S, McLeod H, Harnett PR, Brown
R, DeFazio A and Chenevix-Trench G: ABCB1 (MDR 1)
polymorphisms and progression-free survival among women with
ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin
Cancer Res. 14:5594–5601. 2008. View Article : Google Scholar
|
|
5
|
Turk V, Turk B and Turk D: Lysosomal
cysteine proteases: facts and opportunities. EMBO J. 20:4629–4633.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Athanassiadou P, Sakellariou V, Petrakakou
E, Athanassiades P, Zerva C, Liossi A and Michalas S: Cathepsin D
immunoreactivity in ovarian cancer: correlation with prognostic
factors. Pathol Oncol Res. 4:103–107. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nishida Y, Kohno K, Kawamata T, Morimitsu
K, Kuwano M and Miyakawa I: Increased cathepsin L levels in serum
in some patients with ovarian cancer: comparison with CA125 and
CA72–4. Gynecol Oncol. 56:357–361. 1995.PubMed/NCBI
|
|
8
|
Kolwijck E, Kos J, Obermajer N, Span PN,
Thomas CM, Massuger LF and Sweep FC: The balance between
extracellular cathepsins and cystatin C is of importance for
ovarian cancer. Eur J Clin Invest. 40:591–599. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nishikawa H, Ozaki Y, Nakanishi T,
Blomgren K, Tada T, Arakawa A and Suzumori K: The role of cathepsin
B and cystatin C in the mechanisms of invasion by ovarian cancer.
Gynecol Oncol. 92:881–886. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jedeszko C and Sloane BF: Cysteine
cathepsins in human cancer. Biol Chem. 385:1017–1027. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gocheva V and Joyce JA: Cysteine
cathepsins and the cutting edge of cancer invasion. Cell Cycle.
6:60–64. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mohamed MM and Sloane BF: Cysteine
cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer.
6:764–775. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lankelma JM, Voorend DM, Barwari T,
Koetsveld J, Van der Spek AH, De Porto AP, Van Rooijen G and Van
Noorden CJ: Cathepsin L, target in cancer treatment? Life Sci.
86:225–233. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yan S, Sameni M and Sloane BF: Cathepsin B
and human tumor progression. Biol Chem. 379:113–123.
1998.PubMed/NCBI
|
|
15
|
Lah TT and Kos J: Cysteine proteinases in
cancer progression and their clinical relevance for prognosis. Biol
Chem. 379:125–130. 1998.PubMed/NCBI
|
|
16
|
Rao JS: Molecular mechanisms of glioma
invasiveness: the role of proteases. Nat Rev Cancer. 3:489–501.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Szpaderska AM and Frankfater A: An
intracellular form of cathepsin B contributes to invasiveness in
cancer. Cancer Res. 61:3493–3500. 2001.PubMed/NCBI
|
|
18
|
Premzl A, Zavasnik-Bergant V, Turk V and
Kos J: Intracellular and extracellular cathepsin B facilitate
invasion of MCF-10A neoT cells through reconstituted extracellular
matrix in vitro. Exp Cell Res. 283:206–214. 2003. View Article : Google Scholar
|
|
19
|
Scorilas A, Fotiou S, Tsiambas E, Yotis J,
Kotsiandri F, Sameni M, Sloane BF and Talieri M: Determination of
cathepsin B expression may offer additional prognostic information
for ovarian cancer patients. Biol Chem. 383:1297–1303. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang M, Tang J, Liu S, Yoshida D and
Teramoto A: Expression of cathepsin B and microvascular density
increases with higher grade of astrocytomas. J Neurooncol. 71:3–7.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
He X, Brenchley PE, Jayson GC, Hampson L,
Davies J and Hampson IN: Hypoxia increases heparanase-dependent
tumor cell invasion, which can be inhibited by antiheparanase
antibodies. Cancer Res. 64:3928–3933. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ricciardelli C and Rodgers RJ:
Extracellular matrix of ovarian tumors. Semin Reprod Med.
24:270–282. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hogdall EV, Christensen L, Hogdall CK,
Blaakaer J, Gayther S, Jacobs IJ, Christensen IJ and Kjaer SK:
Prognostic value of estrogen receptor and progesterone receptor
tumor expression in Danish ovarian cancer patients: from the
‘MALOVA’ ovarian cancer study. Oncol Rep. 18:1051–1059.
2007.PubMed/NCBI
|
|
24
|
Falcetta F, Lupi M, Colombo V and Ubezio
P: Dynamic rendering of the heterogeneous cell response to
anticancer treatments. PLoS Comput Biol. 9:e10032932013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Siewinski M, Saleh Y, Gryboc M, Murawski
M, Ekonjo GB, Ziolkowski P, Janocha A and Symonowicz K:
Determination of cysteine peptidases-like activity and their
inhibitors in the serum of patients with ovarian cancer treated by
conventional chemotherapy and vitamin E. J Exp Ther Oncol.
4:189–193. 2004.PubMed/NCBI
|
|
26
|
Warwas M, Haczynska H, Gerber J and Nowak
M: Cathepsin B-like activity as a serum tumour marker in ovarian
carcinoma. Eur J Clin Chem Clin Biochem. 35:301–304.
1997.PubMed/NCBI
|
|
27
|
Kolwijck E, Massuger LF, Thomas CM, Span
PN, Krasovec M, Kos J and Sweep FC: Cathepsins B, L and cystatin C
in cyst fluid of ovarian tumors. J Cancer Res Clin Oncol.
136:771–778. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Epelman M, Chikwava KR, Chauvin N and
Servaes S: Imaging of pediatric ovarian neoplasms. Pediatr Radiol.
41:1085–1099. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Levicar N, Dewey RA, Daley E, Bates TE,
Davies D, Kos J, Pilkington GJ and Lah TT: Selective suppression of
cathepsin L by antisense cDNA impairs human brain tumor cell
invasion in vitro and promotes apoptosis. Cancer Gene Ther.
10:141–151. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang Z and Cox JL: Cathepsin L increases
invasion and migration of B16 melanoma. Cancer Cell Int. 7:82007.
View Article : Google Scholar : PubMed/NCBI
|
